Clinical Trial Success Uncertainty: The success of Genmab's investigational drug candidates in clinical trials is not guaranteed, and failures at any stage could lead to significant delays, increased costs, or termination of development, impacting future revenue streams.

Regulatory Approval Challenges: Even with positive clinical trial data, obtaining marketing approvals from regulatory bodies such as the FDA or EMA is complex and uncertain, potentially delaying or preventing commercialization of new drugs.

Intense Market Competition: Genmab faces significant competition from other pharmaceutical and biotechnology companies developing similar or alternative therapies, which could limit the market potential and pricing power of its approved and pipeline products.